NCT03479125View on ClinicalTrials.gov

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

TerminatedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

August 31, 2019

Study Completion Date

September 30, 2019

Conditions
Liver DiseasesLiver FibrosisLiver CirrhosisNASH FibrosisDecompensated Non-Alcoholic Steatohepatitis CirrhosisOrthotopic Liver Transplantation
Interventions
DIAGNOSTIC_TEST

Ultrasound

Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.

Trial Locations (3)

38138

Gastro One, Germantown

74104

Options Health Research, LLC, Tulsa

92377

Inland Empire Liver Foundation, Rialto

Sponsors
All Listed Sponsors
lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT03479125 - Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo | Biotech Hunter | Biotech Hunter